Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cinclus Pharma Holding AB ( (SE:CINPHA) ).
Cinclus Pharma Holding AB announced the upcoming release of its third-quarter report for 2025, scheduled for November 20. The report will be presented by the CEO and CFO, followed by a Q&A session, and will be accessible via webcast and teleconference. This event is significant as it provides insights into the company’s financial health and strategic direction, potentially impacting its stakeholders and market position.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and upper gastrointestinal tract disorders. Their leading drug candidate, linaprazan glurate, aims to treat gastroesophageal reflux disease (GERD) more effectively than current treatments. The company is advancing linaprazan glurate through clinical trials to address the needs of approximately 10 million patients with severe GERD in the US and EU.
Average Trading Volume: 63,624
Technical Sentiment Signal: Buy
Current Market Cap: SEK788.4M
For detailed information about CINPHA stock, go to TipRanks’ Stock Analysis page.